These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 30317986)
61. Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia. Kosmas CE; Muñoz Estrella A; Sourlas A; Silverio D; Hilario E; Montan PD; Guzman E Diseases; 2018 Jul; 6(3):. PubMed ID: 30011788 [TBL] [Abstract][Full Text] [Related]
62. PCSK9: a key modulator of cardiovascular health. Seidah NG; Awan Z; Chrétien M; Mbikay M Circ Res; 2014 Mar; 114(6):1022-36. PubMed ID: 24625727 [TBL] [Abstract][Full Text] [Related]
63. PCSK9 Inhibition and Atherosclerosis: Current Therapeutic Option and Prospection. Pandey P; Zhao C; Liu B Methods Mol Biol; 2020; 2204():133-143. PubMed ID: 32710321 [TBL] [Abstract][Full Text] [Related]
64. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. Joseph L; Robinson JG Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907 [TBL] [Abstract][Full Text] [Related]
65. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9. Seidah NG; Abifadel M; Prost S; Boileau C; Prat A Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219 [TBL] [Abstract][Full Text] [Related]
66. PCSK9 and infection: A potentially useful or dangerous association? Khademi F; Momtazi-Borojeni AA; Reiner Ž; Banach M; Al-Rasadi KA; Sahebkar A J Cell Physiol; 2018 Apr; 233(4):2920-2927. PubMed ID: 28574577 [TBL] [Abstract][Full Text] [Related]
67. Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin/kexin type 9. Chackerian B; Remaley A Curr Opin Lipidol; 2016 Aug; 27(4):345-50. PubMed ID: 27389630 [TBL] [Abstract][Full Text] [Related]
68. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab. Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604 [TBL] [Abstract][Full Text] [Related]
69. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab. Desai NR; Giugliano RP; Wasserman SM; Gibbs JP; Liu T; Scott R; Sabatine MS JAMA Cardiol; 2017 May; 2(5):556-560. PubMed ID: 28122070 [TBL] [Abstract][Full Text] [Related]
70. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans. Reyes-Soffer G; Pavlyha M; Ngai C; Thomas T; Holleran S; Ramakrishnan R; Karmally W; Nandakumar R; Fontanez N; Obunike J; Marcovina SM; Lichtenstein AH; Matthan NR; Matta J; Maroccia M; Becue F; Poitiers F; Swanson B; Cowan L; Sasiela WJ; Surks HK; Ginsberg HN Circulation; 2017 Jan; 135(4):352-362. PubMed ID: 27986651 [TBL] [Abstract][Full Text] [Related]
71. The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins. Athyros VG; Tziomalos K; Doumas M; Sfikas G; Karagiannis A Curr Pharm Des; 2017; 23(10):1477-1483. PubMed ID: 28128061 [TBL] [Abstract][Full Text] [Related]
72. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else? Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526 [TBL] [Abstract][Full Text] [Related]
73. Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation. Karagiannis AD; Liu M; Toth PP; Zhao S; Agrawal DK; Libby P; Chatzizisis YS Curr Atheroscler Rep; 2018 Mar; 20(4):20. PubMed ID: 29525934 [TBL] [Abstract][Full Text] [Related]
74. Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics. Gauthier MS; Awan Z; Bouchard A; Champagne J; Tessier S; Faubert D; Chabot K; Garneau PY; Rabasa-Lhoret R; Seidah NG; Ridker PM; Genest J; Coulombe B J Clin Lipidol; 2018; 12(4):1027-1038. PubMed ID: 29699916 [TBL] [Abstract][Full Text] [Related]
75. Statins and Their Effect on PCSK9-Impact and Clinical Relevance. Taylor BA; Thompson PD Curr Atheroscler Rep; 2016 Aug; 18(8):46. PubMed ID: 27315084 [TBL] [Abstract][Full Text] [Related]
76. Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes. Ramanathan A; Gusarova V; Stahl N; Gurnett-Bander A; Kyratsous CA PLoS One; 2016; 11(4):e0154498. PubMed ID: 27115873 [TBL] [Abstract][Full Text] [Related]
77. Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis. Peng W; Qiang F; Peng W; Qian Z; Ke Z; Yi L; Jian Z; Chongrong Q Int J Cardiol; 2016 Nov; 222():119-129. PubMed ID: 27494723 [TBL] [Abstract][Full Text] [Related]
78. PCSK9 inhibition: the dawn of a new age in cholesterol lowering? Preiss D; Mafham M Diabetologia; 2017 Mar; 60(3):381-389. PubMed ID: 28025677 [TBL] [Abstract][Full Text] [Related]
79. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies. Gumbiner B; Joh T; Liang H; Wan H; Levisetti M; Vana AM; Shelton DL; Forgues P; Billotte S; Pons J; Baum CM; Garzone PD Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29078037 [TBL] [Abstract][Full Text] [Related]